In findings that open the door to a completely different approach to curing HIV infections, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time shown that a novel compound effectively suppresses production of the virus in chronically infected cells, and prevents viral rebound, even when those infected cells are subjected to vigorous stimulation.
The study, led by TSRI Associate Professor Susana Valente, was published online Oct. 17 before print in the journal Cell Reports.
“No other anti-retroviral used in the clinic today is able to completely suppress viral production in infected cells in vivo,” Valente said. “When combining this drug with the standard cocktail of anti-retrovirals used to suppress infection in humanized mouse models of HIV-1 infection, our study found a drastic reduction in virus RNA present—it is really the proof-of-concept for a ‘functional cure.’”
Valente, a pioneer in this new approach, calls it “Block-and-Lock”—the approach blocks reactivation of the virus in cells, even during treatment interruptions, and locks HIV into durable state of latency.
Valente and her colleagues use a derivative of a natural compound called didehydro-Cortistatin A (dCA), which blocks replication in HIV-infected cells by inhibiting the viral transcriptional activator, called Tat, halting viral production, reactivation and replenishment of the latent viral reservoir.
“Combining dCA with anti-retroviral therapy accelerates HIV-1 suppression and prevents viral rebound after treatment interruption, even during strong cellular activation,” Valente said. “It’s important to note that our study uses the maximum tolerable dose of the drug—with virtually no side effects.”
The scientists studied the combination therapy in a mouse model of HIV latency and persistence. Once the combined treatment regimen was halted, viral rebound was delayed up to 19 days, compared with just seven days in mouse models receiving only anti-retroviral treatment.
“This demonstrates the potential of ‘block-and-lock’ strategies,” said TSRI Research Associate Cari F. Kessing, co-first author of the study. “This study shows that a ‘functional cure’ approach can succeed in reducing residual virus in the blood during anti-retroviral treatment and limiting viral rebound during treatment interruption.”
“In half of the dCA treated mice, the virus was undetectable for 16 days after all treatment was halted,” said the University of North Carolina’s Christopher Nixon, another first author.
“We blocked Tat, and the cell’s machinery did the rest,” said TSRI Research Associate Chuan Li, a coauthor of the study. “The result was that the HIV promoter becomes repressed.”
Valente pointed out that the animal models were exposed to just a single month of treatment. “That’s a relatively short period of time,” she said. “We think longer treatments will result in longer, or even permanent, rebound delays. The question is how long? We’re studying that now.”
Because any viral rebound of HIV comes with a host of adverse effects, Valente noted, blocking that rebound would automatically reduce those effects.
“This is the only class of drugs that stops infected cells from making viruses outright,” said Valente. “All current antivirals work later in the viral lifecycle, so only a HIV transcriptional inhibitor like dCA can stop the side effects of low-level virus production.”
The Latest on: HIV
- MedWatch Daily Digest: HIV vaccine update and moreon April 7, 2021 at 11:08 am
A promising advance in the search for an HIV vaccine. The International AIDS Vaccine Initiative and The Scripps Research Institute are developing a vaccine that helps the body create broadly ...
- Calls for CDC investigation into ‘most concerning’ HIV outbreak in West Virginia after 35 cases reportedon April 7, 2021 at 10:21 am
DOZENS of HIV cases have been reported in West Virginia – and lawmakers are calling for the Centers for Disease Control and Prevention to investigate. Senator Joe Manchin sent the CDC an inquiry ...
- Best Life: New research helping treat and prevent HIVon April 7, 2021 at 4:59 am
April 10 is National Youth HIV and Aids Awareness Day. Today, about 1.2 million people in the United States are living with HIV. We’ve come a long way in diagnosing, treating, and preventing the virus ...
- HIV vaccine stimulates 'rare immune cells' in early human trialson April 7, 2021 at 4:01 am
A new vaccine for HIV is raising excitement after its first in-human trials showed 97% success at stimulating a rare set of immune cells that play a key role in fighting the virus. The vaccine ...
- Research shows promising development in hunt for HIV vaccineon April 6, 2021 at 4:28 pm
On Location: April 6, 2021 After more than 30 years of attempts, there may be a promising advance in the search for a vaccine for HIV, the virus that causes AIDS if left untreated. Now ...
- An HIV Vaccine Based On The Moderna COVID Vaccine Is Getting Promising Resultson April 6, 2021 at 3:01 pm
A new HIV vaccine, based on the Moderna COVID-19 inoculation, has shown a 97% antibody response rate in Phase I clinical trials. Currently, HIV affects more than 38 million people globally. If ...
- People with HIV at high risk for intimate partner violenceon April 6, 2021 at 1:10 pm
New data from the Centers for Disease Control and Prevention (CDC) show that one in four adults with HIV in the United States has experienced intimate partner violence (IPV), which disproportionately ...
- New HIV vaccine candidate could be a gamechangeron April 6, 2021 at 12:02 pm
Researchers gave participants the vaccine or a placebo in a phase 1 clinical trial of the HIV vaccine candidate. Participants were able to produce the targeted antibodies in response to the vaccine.
- Leader needed to fight another global pandemic — HIVon April 6, 2021 at 11:31 am
The pandemic has disrupted access to HIV testing, which is critical to disease surveillance and informed effective responses. It has brought new barriers to accessing care and antiretroviral treatment ...
- Are Back Pain and HIV Connected?on April 6, 2021 at 7:04 am
People with HIV often experience chronic back pain and pain in other parts of their bodies as well. We take a look at how common back pain is in people with HIV, what causes it, and tips for ways to ...
via Google News and Bing News